Compare FRPH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | AKBA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 380.4M |
| IPO Year | 1995 | 2014 |
| Metric | FRPH | AKBA |
|---|---|---|
| Price | $21.60 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 64.4K | ★ 2.5M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $41,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $135.88 | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $20.53 | $1.14 |
| 52 Week High | $29.68 | $4.08 |
| Indicator | FRPH | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 45.88 |
| Support Level | N/A | $1.30 |
| Resistance Level | $24.59 | $1.55 |
| Average True Range (ATR) | 0.73 | 0.07 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 37.14 | 6.25 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.